Conditions: Psoriasis Vulgaris
Keywords: psoriasis plaque vulgaris phase 1 randomized double-blind topical safety
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 15
Healthy volunteers: no

Brief summary:
This is a vehicle and comparator controlled Proof of Mechanism (PoM) trial to evaluate the effect on psoriasis disease activity and safety of topically applied PF 06263276 in subjects with psoriasis vulgaris.

Detailed description:

Arms:
arm 1: Study treatments 1-6 Study drug, vehicle, Tofacitinib, vehicle, Daivonex solution and ointment

Interventions: intervention 1: PF06263276 intervention 2: Vehicle intervention 3: 2%Tofacitinib Ointment intervention 4: Vehicle intervention 5: Daivonex intervention 6: Daivonex Ointment
Intervention descriptions: intervention 1: 4% PF 06263276 solution Daily dosage: approximately 8 mg PF 06263276 QD intervention 2: Active ingredient-free vehicle to 4% solution intervention 3: Daily Dosage: approximately 4 mg tofacitinib intervention 4: Active ingredient-free vehicle to 2% Ointment intervention 5: Daivonex solution (50 ug/ml Calcipotriol) Daily Dosage of calcipotriol: approximately 0.01 mg intervention 6: Daivonex ointment (50 ug/g Calcipotriol) Daily Dosage of calcipotriol: approximately 0.01 mg

Protocol document: